Clinical Trial News and Research

RSS

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Inovio Pharmaceuticals, Inc. , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX-B, a DNA vaccine for the prevention of HIV infection.

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

5-lipoxygenase protein modulates amyloid beta formation linked to Alzheimer's disease

A protein known to exist in the brain for more than 30 years, called 5-lipoxygenase, has been found to play a regulatory role in the formation of the amyloid beta in the brain, the major component of plaques implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

18 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Titan Pharmaceuticals, Inc. today announced that data from its Phase 3 clinical development program for Probuphine were presented at the Society for Neuroscience Annual Meeting, being held Nov. 13-17 in San Diego.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Vical enters agreement with GenomIdea to develop DNA vaccine for pandemic influenza

Vical Incorporated today announced that the company has entered into an evaluation and supply agreement with GenomIdea Inc., a subsidiary of AnGes MG, Inc., for the development of a DNA vaccine for livestock against pandemic influenza.

17 Nov 2010

Combination of two devices increases long-term survival in cardiac arrest patients

A combination of two devices could save the lives of several thousand cardiac arrest patients each year if implemented nationwide, suggests results of a clinical trial presented at today's American Heart Association Resuscitation Science Symposium.

17 Nov 2010

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

The Belgian biotechnology company, Cardio3 BioSciences a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases today announces positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure(R), designed as a novel stem cell therapy for heart failure based on breakthrough technology.

17 Nov 2010

Fat-derived stem cells can boost heart function following acute attack

Fat cells liposuctioned from a patient's belly can safely boost heart function after a heart attack, according to a first-of-its-kind study presented at the American Heart Association's Scientific Sessions 2010.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

The National Institutes of Health (NIH) has awarded $10 million to the Georgia Institute of Technology, Emory University and PATH, a Seattle-based nonprofit organization, to advance a technology for the painless, self-administration of flu vaccine using patches containing tiny microneedles that dissolve into the skin.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today the acquisition of the world's largest cryo-preserved human cancer tissue bank—more than 144,000 specimens procured over 20 years. The company acquired the tumor bank, along with properly de-identified clinical information and validated test procedures, as part of a major acquisition of key assets formerly owned by Oncotech.

17 Nov 2010

Clinical Trial News and Research

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

5-lipoxygenase protein modulates amyloid beta formation linked to Alzheimer's disease

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

BioSante announces sale of oncolytic virus technology to Cold Genesys

VX-770 drug candidate improves lung function in people with cystic fibrosis

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Vical enters agreement with GenomIdea to develop DNA vaccine for pandemic influenza

Combination of two devices increases long-term survival in cardiac arrest patients

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

Fat-derived stem cells can boost heart function following acute attack

Targeted therapies could treat a broad range of cancers: Research

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

NIH awards $10 million to advance technology for painless influenza vaccine delivery patch

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

MRL announces acquisition of world's largest cryo-preserved human cancer tissue bank

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News